Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

694 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Dahlöf B, et al. Among authors: kjeldsen se. Lancet. 2002 Mar 23;359(9311):995-1003. doi: 10.1016/S0140-6736(02)08089-3. Lancet. 2002. PMID: 11937178 Clinical Trial.
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman JM, Snapinn S; LIFE study group. Lindholm LH, et al. Among authors: kjeldsen se. J Hypertens. 2002 Sep;20(9):1879-86. doi: 10.1097/00004872-200209000-00035. J Hypertens. 2002. PMID: 12195132 Clinical Trial.
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, Aurup P, Edelman J, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H; LIFE (Losartan Intervention for Endpoint Reduction) Study Group. Kjeldsen SE, et al. JAMA. 2002 Sep 25;288(12):1491-8. doi: 10.1001/jama.288.12.1491. JAMA. 2002. PMID: 12243636 Clinical Trial.
Comparison of the SCOPE and LIFE results.
Kjeldsen SE, Dahlöf B, Devereux RB, Lindholm LH, Nieminen MS, Oparil S, Wedel H; SCOPE Study Group. Kjeldsen SE, et al. J Hypertens. 2003 Sep;21(9):1772-3; author reply 1773. doi: 10.1097/00004872-200309000-00030. J Hypertens. 2003. PMID: 12923412 No abstract available.
Recent hypertension guidelines: JNC-7 and 2003 ESH/ESC.
Himmelmann A, Kjeldsen SE, Hedner T. Himmelmann A, et al. Among authors: kjeldsen se. Blood Press. 2003;12(4):196-7. doi: 10.1080/08037050310015854. Blood Press. 2003. PMID: 14596354 No abstract available.
694 results